Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 15.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic genotype 1, 2, 3, or 6 HCV infection~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment) (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
- Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment) (Type: EXPERIMENTAL): SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
- Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease) (Type: EXPERIMENTAL): LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
- Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease) (Type: EXPERIMENTAL): LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
- Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
- Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
- Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
- Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
- Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
- Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic) (Type: EXPERIMENTAL): SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
- Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic) (Type: EXPERIMENTAL): SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
- Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic) (Type: EXPERIMENTAL): SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
- Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic) (Type: EXPERIMENTAL): SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
- Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment) (Type: EXPERIMENTAL): LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
- Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete